Be sure to check our sister interview main ratings news website

Motif Bio plc progressing trials efficiently with latest update

Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, has given DirectorsTalk an update to REVIVE-1, one of Motif Bio’s two Phase 3 clinical trials currently enrolling patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI).

Patient enrollment for REVIVE-1 has exceeded projections and data readout is now expected in the second quarter of 2017, rather than the second half of 2017, as previously stated. REVIVE-2 remains on track with data readout continuing to be expected in the second half of 2017.

 

Read in Full
Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    Motif Bio Plc

    More articles like this

    Motif Bio Plc

    Motif Bio plc Proposed Placing to raise approximately £19.4m

    2nd June 2017

    Motif Bio plc (LON:MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today its intention to raise approximately £19.4 million (US$25 million), before expenses, by way of a conditional placing with new and

    Motif Bio Plc

    Motif Bio PLC Reports Year-End 2016 Financial Results

    2nd May 2017

    Motif Bio PLC (LON:MTFB), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, today announced financial results for the year ended December 31, 2016. Motif Bio made significant progress in 2016 towards our goal of

    Motif Bio Plc

    Motif Bio plc Update post NASDAQ IPO

    20th January 2017

    Motif Bio plc (LON:MTFB, NASDAQ:MTFB), is a late clinical stage antibiotic development company. The company completed its IPO on NASDAQ in November last year raising $25m before expenses. With the funds from the IPO the company

    Motif Bio Plc

    Motif Bio plc appoint ex NASDAQ listed Tyme Technologies CFO

    18th January 2017

    Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, has told DirectorsTalk that Robert Dickey IV has been appointed as Chief Financial Officer. Mr. Dickey is an accomplished financial professional

    Motif Bio Plc

    Motif Bio PLC Update on US Public Offering

    31st October 2016

    Motif Bio plc (LON:MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, further to its announcement of 9 August 2016, said today that it is continuing to work towards pricing of its proposed public

    Motif Bio Plc

    Motif Bio plc 2 posters at ID Week in New Orleans

    15th September 2016

    Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, has told DirectorsTalk that it will be presenting two poster studies at IDWeek, October 26 to 30 in New Orleans, USA.

    Motif Bio Plc

    Motif Bio plc playback facility on analysts conference call

    25th April 2016

    Motif Bio plc (AIM: MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics, has told DirectorsTalk that following the conference call for analysts and investors that took place on Wednesday 20 April 2016 a

    © 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.